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Summary: An elevated erythrocyte sedimentation rate is generally regarded as an unspeciflc and mostly
pathological indicator of inflammation or tumour. However, we have determined the concentrations of
plasma/serum proteins that influence the erythrocyte sedimentation rate in numerous samples from several
groups of patients with different diseases, including 2 forms of cancer. Equations have been developed by
which the l h value of erythrocyte sedimentation rate can be expressed as the sum of disease-specific coefficients
for each protein multiplied by the measured concentrations of the respective proteins. These equations are
shown to be disease-specific with 64 — 93% probability. Such equations may thus form the basis for differential
diagnosis.
Introduction
Since the fundamental work of Fähraeus (1) and Wes-
tergren (2), an elevated erythrocyte sedimentation rate
has been looked upon as an unspecific and mostly
pathological indicator, which is often elevated on both
acute and chronic inflammation states, various types
of cancer and during the last months of pregnancy.
Even in the mentioned studies, it was recognized that
an elevated erythrocyte sedimentation rate is usually
accompanied by an increased fibrinogen concentra-
tion. We showed in 1966 (3) that elevated concentra-
tions of several plasma proteins, such as coeruloplas-
min, haptoglobin or o^-macroglobulin, can also cause
an elevated erythrocyte sedimentation rate. We named
these proteins agglomerins (4).
Evidence for some disease-related specificity of the
erythrocyte sedimentation rate was first mentioned in
This research was supported in part by Texmana AG,
CH-6052 Hergiswil, Switzerland.
1975 (5). We observed that irrespective of age, sex or
duration of diseases in different groups of diseases
with elevated erythrocyte sedimentation rate, the val-
ues of the correlation coefficients for the concentra-
tion of different agglomerins had a disease specific
order. This observation is supported by the finding
that the ratios between the concentrations of the in-
vestigated plasma proteins remain fairly constant dur-
ing the course of a heart infarct or other diseases (5).
Also, the observation that an elevated erythrocyte
sedimentation rate is decreased to different extents by
prednisolone, depending on the accompanying dis-
ease, favours the assumption that the erythrocyte
sedimentation rate mechanism is specific (6). This
prompted the following model study on patient
groups with different diseases, aimed at the develop-
ment of a procedure for differential diagnosis, based
on analysis of the relationship between elevated eryth-
rocyte sedimentation rate and the concentrations of
certain plasma proteins.
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Materials and Methods
The study consists of three parts with respectively four (part I)
and two (part II and III) groups of patients, each group con-
sisting of patients with an identical disease. No selection for the
patient age and the stage of their diseases was made.
Serum and citrated blood (1+4) were obtained from the pa-
tients and 5 ml of the blood was centrifuged (10 min, 3000 g).
To normalize the concentrations of erythrocytes, a mixture of
1 ml of the supernatant plasma and 0.5 ml packed erythrocytes
was used. The further procedure for determining the l h eryth-
rocyte sedimentation rate was performed according to the rules
for standardization of the erythrocyte sedimentation rate (7).
The correlation coefficient r of duplicate measurements of the
l h value was 0.96. Serum and plasma samples were stored at
-70 °C before analysis.
In the plasma the concentration of flbrinogen was determined
by immunodiffusion (NOR-Partigen plates Behring-Werke D-
3550 Marburg/Lahn, Germany). In sera, the concentrations of
the following serum proteins were measured by immunodifTu-
sion (Partigenplates; Behringwerke, D-3550 Marburg/Lahn,
Germany): C-reactive protein, immunoglobulin A, immuno-
globulin G and immunoglobulin M. In parts I and III of the
study the following serum proteins were further assayed by the
method of Clarke-Freeman (8): albumin, acid-at-glycoprotein,
arantitrypsin, oci-lipoprotein, a2-macroglobulin, complement
C3, coeruloplasmin, haptoglobin, prealbumin, transferrin.
The mean imprecision of the protein concentration values meas-
ured by the Clarke-Freeman method was CV < ± 5.5%. In
part II zone immunoelectrophoresis assay (ZIA) (9) was used
instead of the method of Clarke-Freeman for measurement of
the respective protein concentrations. The imprecision of zone
immunoelectrophoresis assay is CV ±3% (10).
By measuring the erythrocyte sedimentation rate and the
plasma/serum protein concentrations of every patient, we ob-
tained one block of values for each group of patients.
Pat ients
Patients came from the University clinics of Munich and Lü-
beck (Germany) with clinically asserted diagnoses.
Part I
Four groups of patients were investigated with the following
diseases: erysipela, malignant melanoma, multiple sclerosis and
carcinoma of the uterus. These 4 groups were chosen as ex-
amples of an acute inflammation, a very acute tumour, a chronic
inflammation and a tumour with a more protracted course. All
erysipela patients had been hospitalized due to the severity of
their disease. Table 1 shows the mean age and the sex distri-
bution as well as the mean duration time of acute multiple
sclerosis patients and of the other groups when the blood was
taken. The melanoma patients were hospitalized because of
known or suspected metastases. The time since operation of
the primary tumour is indicated in table 1. The diagnosis of
patients with multiple sclerosis was ensured by the typical
multiple sclerosis liquor inflammation state and computer
NMR tomography (11). The blood of the patients with uterus
carcinoma had been taken before the operation of the tumour.
Part II
In this part the values of two other groups of multiple sclerosis
and uterine carcinoma patients different from those in part I
were investigated.
Part III
In this part, the values of the patients of part I with multiple
sclerosis were compared with those of another group with
different kinds of inflammation of the central or peripheral
neurological system, such as encephalitis, herpes zoster or neu-
ritis.
Tab. 1. Clinical data of the patient groups (n.d. = not determined)
Part of
study
Disease Mean age
(years)
1 h-mean ESR
values (mm)
Mean duration
of disease
1 Erysipela 40 11/29 42.2 ± 10.4 88.93 ± 26.62
ESR = erythrocyte sedimentation rate
4.0 ± 3.5 days
2
3
Malignant
melanoma
Multiple
sclerosis
Uterine
carcinoma
Multiple
sclerosis
Uterine
carcinoma
Multiple
sclerosis
Inflammatory
diseases of the
nervous system
13
15
22
19
19
15
15
8/ 5
11 8
0/22
13/ 6
0/19
11 8
9 / 6
40.5
35.2
58.2
40.1
56.1
35.2
30.1
+
±
±
±
±
±
±
15.3
15.0
10.0
12.9
12.3
15.0
9.5
75.85
33.03
61.88
37.13
56.66
33.03
52.16
±
±
±
±
±
±
±
44.90
25.33
23.18
26.72
19.57
25.33
27.04
1.4 ±
5.2 ±
n.d.
n.d.
n.d.
5.2 ±
n.d.
2.5 years
3.5 years
3.5 years
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Calcu la t ion (12)
At the beginning of the study we calculated a simple linear
regression function between erythrocyte sedimentation rate and
the concentration for each single protein, using all the individual
values from every group. After that, the difference between the
calibration (regression line) value and the measured value was
determined for each plasma protein concentration of every
patient. The disease with the greatest number of minimal dif-
ferences was taken as the diagnosis. However, by this procedure
the number of errors was considerably greater compared with
the multiple regression method described below.
By the method of stepwise linear regression a certain T-value
of significance was stated. Then in each group the regression
equation with all parameters (plasma/serum concentration
against erythrocyte sedimentation rate) was calculated, and all
parameters transgressing the chosen T-value was eliminated
stepwise.
The basis of these calculations was each block of values from
patients with the different diseases. The plasma/serum protein
concentration of each patient was expressed in percent of the
assigned normal values of human serum (Behring- Werke, D-
3550 Marburg/Lahn, Germany). In the first part of the study
the plasma/serum values were normalized so that the values
equalling the assigned normal values became zero. Higher val-
ues are given in percent of the assigned values. In the two other
parts of the study, the normal values were assigned a value of
100.
For each group this procedure led to a vector of coefficients
for every parameter of the equation. The coefficients of the
equations were obtained by using the sum of squares of devi-
ations to obtain a minimum when using all measured concen-
trations of plasma/serum proteins of all patients of one block.
We then compared again in every part of the study the calcu-
lated erythrocyte sedimentation rate of each patient with the
measured erythrocyte sedimentation rate. The value closest to
one of the values of an equation was taken for the probable
diagnosis.
For these calculations we developed a program in Pascal. To
test the quality of the regression we used three values: the T-
test (the significance of impact of a certain coefficient of an
equation) the F-test (the probability of the independence of
erythrocyte sedimentation rate (ESR) on certain parameters of
the model) and the Revalue (the multiple correlation coeffi-
cient):
Σ(Ε8Κι - ESR)2
i - ESR)2
R2 = 1 _
ESRj = measured ESR of a patient
ESR = "Calculated" ESR
ESR = mean value of ESR of a group.
In this way equations of the following type were obtained:
1-hour value of
ESR =
c, χ Alb 4- c2 χ Ala 4- c3 χ Coe 4- ... 4- c]5 χ Tra.
Cj to ct5 are fixed coefficients, and the three letters represent
the concentrations of the plasma/serum proteins albumin, otr
antitrypsin, coeruloplasmin, transferrin in percentage of the
normal values.
We applied every equation to the concentrations of all the
plasma/serum proteins which had been estimated in each indi-
vidual in each block. Moreover, within the blocks those proteins
were excluded which had no or almost no influence on the
variability of the erythrocyte sedimentation rate values ex-
pressed by R2.
Results
In part 1,40 patients with erysipela, 13 with malignant
melanoma, 15 with multiple sclerosis and 22 with
uterine carcinoma were studied. Table 2 shows the
resulting equations. In part II we measured the eryth-
rocyte sedimentation rate values and the plasma/se-
rum protein profiles of 19 patients with multiple scle-
rosis and 19 with uterine carcinoma. In table 4 the
resulting equation is given. In part III the values of
the 15 patients with multiple sclerosis of part 1, and
of 15 patients with no multiple sclerosis inflammation
of the nervous system formed the basis for the two
equations (tab. 6). The equations also gave some
negative correlations, especially with albumin.
Table 2 demonstrates that in the four equations of
part I the corresponding coefficients for specific
plasma/serum protein concentrations showed distinct
differences, for example for fibrinogen 0.86, 0.26, 2.40
and 2.05. Therefore, we supposed that the concentra-
tion values taken as a whole of any patient of the four
blocks would best fit the equation of their own block,
Tab. 2. Equations for four diseases using the plasma concen-
trations of 10 or 9 plasma proteins in part I of the
study. ESR = Erythrocyte sedimentation rate
Proteins:
acid arglycoprotein
albumin
ocrantitrypsin
coeruloplasmin
complement C3
C-reactive protein
haptoglobin
immunoglobulin A
immunoglobulin G
immunoglobulin M
oct-lipoprotein
oc2-macroglobulin
prealbumin
transferrin
Alg
Alb
Ala
Coe
CC3
Crp
Hap
IgA
IgG
IgM
All
A2m
Pre
Tra
Equation for erysipela
ESR = 0.84 χ Alb 4- 0.04 χ Alg + 0.23 χ Ala + 0.16
χ Coe -f 0.72 χ Crp + 0.86 χ Fib - 0.19 χ Hap
+ 0.6 χ IgA - 1.95 χ Pre - 2.56 χ Tra 4- 205
Equation for malignant melanoma
ESR = 1.76 χ Alb - 0.89 χ Alg -f 1.32 χ Ala - 0.95
χ Coe + 1.16 χ Crp + 0.26 χ Fib 4- 0.45 χ Hap
4- 1.54 χ IgA - 1.56 χ Pre - 1.95 χ Tra 4- 240
Equation for multiple sclerosis
ESR = - 11.7 χ Alb - 0.07 χ Alg 4- 1.82 χ Ala -f 1.33
χ Coe + 2.4 χ Fib - 0.42 χ Hap - 0.59 χ IgA
-f 1.22 χ Pre 4- 7.32 χ Tra + 141
Equation for uterine carcinoma
ESR = 1.26 χ Alb - 0.26 χ Alg - 1.44 χ Ala + 0.001
χ Coe 4- 2.05 χ Fib 4- 0.32 χ Hap 4- 1.29 χ IgA
- 1.9 χ Pre + 1.96 χ Tra + 128
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Tab. 3. Results of the analysis of erythrocyte sedimentation
rate and plasma/serum profiles of 91 patients from part
II of the study, and the equations using 10 or 9 plasma
proteins shown in table 2.
a) Multiple correlation coefficients (R2) of the four
models. R2 is the multiple correlation coefficient of
each model. It is calculated as the sum of square-
deviations from the real erythrocyte sedimentation
rate of the patients, and its predicted value calcu-
lated from the equation versus the sum of square
differences between the erythrocyte sedimentation
rate and the mean value of all erythrocyte sedimen-
tation rate values from the group. It can be inter-
preted as the proportion of total variability of the
erythrocyte sedimentation rate values within the
group which is explained by the equation.
b) Probabilities in percent of correct or false differential
diagnosis between the four models and diseases.
a)
Patients Models
Erysipela Malignant Multiple Uterine
melanoma sclerosis carcinom
Erysipela | 0.62 | -27.2 -4.7
Malignant 0.24 | 0.99 | -1.15
melanoma
Multiple - 1.05 -13.7 | 0.98 |
sclerosis
Uterine -35.3 -52.18 -3.43
carcinoma
- 1.3
- 0.06
-22.9
0.61
b)
Patients Models
Erysipela Malignant Multiple Uterine
melanoma sclerosis carcinoma
Erysipela 72.5% 2.5%
Malignant 7% [ 86% |
melanoma
Multiple 6.
sclerosis
Uterine 13.
carcinoma
5% 0
5% 4.5%
10%
0
87%
18%
15%
7%
6.5%
64%
and this in fact proves to be correct (tab. 3). The table
shows the probability of the correct or false diagnosis
for the total of the 90 investigated patients: within
the four blocks the correct diagnosis varies between
64 and 87%.
Table 4 contains the two equations of part II of the
study. Again there are distinct differences in the anal-
ogous coefficients of single plasma/serum protein con-
centrations. Accordingly the best fits for a differential
diagnosis within these two blocks amount to 79 and
89% for multiple sclerosis and uterine carcinoma,
respectively (tab. 5).
Tab. 4. Equations obtained in part II of the study. The coeffi-
cients are calculated from the plasma concentrations of
12 selected proteins.
For abbreviations cf. tab. 2
Equation for multiple sclerosis
ESR = - 5.43 χ Alb + 3.67 χ Ala + 6.72 χ A2m -
2.76 χ Coe + 0.21 χ Crp + 2.5 χ Fib + 0.21 χ
Hap + 1.03 χ IgA - 1.44 χ IgG + 0.33 χ IgM
+ 1.41 χ Pre + 2.25 χ Tra - 570
Equation for uterine carcinoma
ESR = 1.02 χ Alb - 2.06 χ Ala - 0.20 χ A2m + 0.32
χ Coe - 0.03 χ Crp + 2.46 χ Fib + 0.32 χ Hap
+ 1.13 χ IgA - 0.03 χ IgG + 0.31 χ IgM - 1.48
χ Pre + 2.37 χ Tra - 190
Tab. 5: Results of the analysis of part II of the study (patients
as in table 4):
a) Multiple correlation coefficients of the two models.
b) probabilities of right or false differential diagnosis,
a)
Patients Models
Multiple Urine
sclerosis carcinoma
Multiple sclerosis 0.864 -0.127
Uterine carcinoma -9.020 0.872
b)
Patients Models
Multiple Uterine
sclerosis carcinoma
Multiple sclerosis 79% 21%
Uterine carcinoma 1 1 % | 89% |
The first two parts were merely done to investigate
the principle, i.e. the possibility of differential diagnosis
by analysis of plasma protein concentrations and
erythrocyte sedimentation rate. The result of the third
part is especially promising. Here we compared mul-
tiple sclerosis patients and patients with different in-
flammatory diseases of the nervous system except
multiple sclerosis. The two equations differ distinctly
(tab. 6). The probability for correct diagnosis of the
two disease groups was 93% (tab. 7).
Discussion
Our investigations are based on the following consid-
erations. Former results (5) indicated the possible
existence of functional and disease-specific connec-
tions between the erythrocyte sedimentation rate as a
dependent variable and the concentrations of several
plasma proteins as independent variables.
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Tab. 6. Equations of patients with multiple sclerosis and non-
multiple sclerosis inflammations of the nervous system
in part III of the study. The equations consist of the
concentrations of 10 selected plasma proteins.
For abbreviations cf. tab. 2
Equation for multiple sclerosis
ESR = - 8.08 χ Alb - 0.15 χ Alg + 1.08 χ Ala - 0.58
χ All + 3.11 χ A2m + 0.71 χ CC3 + 4.55 χ
Coe - 0.31 χ Hap + 0.02 χ Pre + 2.48 χ Tra +
360
Equation for inflammations of the nervous system except multiple
sclerosis
ESR = - 11.91 χ Alb + 1.08 χ Alg - 0.04 χ Ala +
1.25 χ All + 2.41 χ A2m + 1.14 χ CC3 + 0.47
χ Coe + 0.09 χ Hap - 0.04 χ Pre - 0.55 χ Tra
+ 477
Tab. 7. Results of the case analysis of part III of the stud\
(patients of table 6) with multiple sclerosis and with
other kinds of inflammation of the nervous system:
a) multiple correlation coefficients of the two models;
b) probabilities of the right or false differential dia-
gnosis.
a)
Patients Models
Multiple
sclerosis
Multiple sclerosis 0.98
Other inflammatory —3.90
diseases of the
nervous system
Inflammatory
diseases of the
nervous system
0.10
0.98
b)
Patients Models
Multiple
sclerosis
Multiple sclerosis 93%
Inflammatory 7%
diseases of the
nervous system
Inflammatory
diseases of the
nervous system
7%
93%
These variables together would form a multidimen-
sional space of parameters inside of which every pa-
tient would be characterized by a certain point. In the
ideal case of measurements without experimental er-
ror, and with no parameters other than the measured
ones influencing the erythrocyte sedimentation rate,
it should be possible to derive equations of curves (in
the simplest case straight lines) which contain all data
points. And if the connections between the concen-
trations of plasma proteins and the erythrocyte sedi-
mentation rate were sufficiently different for different
diseases, one should be able to develop programs for
differential diagnosis between diseases with elevated
erythrocyte sedimentation rate: the greater the differ-
ences between the specific equations of two diseases
the better the diagnostic efficiency.
In practice the data points will not lie on a curve, but
rather be scattered around the expected curve, due to
the experimental error of the measurements and other
non-measured variables influencing the erythrocyte
sedimentation rate.
The characteristic equation for a certain disease would
be best derived by the method of least squares (mul-
tiple linear or non-linear) regression. For all data
points of patients with a certain disease, the expected
value of the distance from this curve is zero. However,
data points of patients with other diseases would be
expected to have distances more or less different from
zero (depending on the differences of the two respec-
tive equations).
For proving such disease-specific equations one would
have to measure the above mentioned variables on a
sufficiently large group of patients with the disease,
so that the addition of further patients would hardly
change the equation derived from the data set. Fur-
thermore, the division of a group of patients into two
subgroups should yield two similar equations.
The procedure of handling of the disease-specific
equations may be explained by an example. Suppose
a malignant melanoma patient had a 1 h-erythrocyte
sedimentation rate of 50 mm. The concentrations of
his plasma/serum proteins are inserted into the ma-
lignant malinoma formula of table 2; if the calculated
erythrocyte sedimentation rate is approximately
50 mm, then the diagnosis is regarded as correct.
Analogies can be made for the other cases in table 2,
if one calculates the erythrocyte sedimentation rate
from the adequate equation by inserting the respective
protein concentration values.
In this study we tested two methods for measuring
the protein concentrations and partly also different
groups of proteins to find optimum conditions. How-
ever, none of these variations improved the results in
any of the three parts.
The multiple sclerosis group values of part I and III
are identical as they stem from the same patients.
However, the corresponding two equations are partly
different. The reason for this is that the proteins used
in the equations of part I and III are only partly
identical. These partial differences in the two equa-
tions show the importance of the choice of the meas-
ured proteins and the interdependence of the coeffi-
cients. The equation of the multiple sclerosis group
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of part II is based on the measurement of the protein
concentrations by zone immunoelectrophoresis assay
(ZIA), while those in part I and III are based on the
Clarke-Freeman method. This may also account for
its difference from to the multiple sclerosis-equations
in part I and II.
From the result of part III two consequences follow:
a) even if only one organ system is involved, specific
plasma/serum protein profiles may indicate distinct
diseases and
b) different unspecific inflammatory diseases of the
nervous system may be combined into one group in
our analysis.
All previous investigations of the possible disease-
specific influence of the plasma/serum protein profile
on the erythrocyte sedimentation rate have failed to
produce positive results (see, e. g. 1. c. (13)). The reason
for this is obviously that the correlations between
protein concentrations and the erythrocyte sedimen-
tation rate are weak. From our work, however, it can
be concluded that the pattern of different plasma/
serum proteins to which the erythrocyte surface is
exposed, i. e. the distribution of influences of the single
plasmaproteins in dependence of the whole of the
proteins seems to be more or less disease-specific and
independent of the values of the erythrocyte sedimen-
tation rate.
The Jesuits of the present study are challanging, but
they do not definitely prove our hypothesis, because
a) the number of cases studied in some classes of
disease was not quite sufficient, and
b) there were problems with the reproducibility of the
protein quantification.
For the practical clinical application of sedimentation
equations it is necessary to obtain sedimentation
equations with general validity
a) by enlarging the number of measured plasma pro-
teins and the number of patients of every disease
group,
b) by using a plasma/serum concentration estimation
method with high reproducibility and clinical practi-
cability,
c) by selecting the best fitting proteins for the corre-
lation calculations, and
d) by determining the equations of further diseases
with elevated erythrocyte sedimentation rate. Obvi-
ously, with improvement, the results of calculations
should be improved accordingly.
Beside this possibility of differential diagnosis, our
findings demonstrate that the feed-back mechanisms
of the concentrations of plasma proteins are interde-
pendent, and that this interdependency is disease-
specific. This may help in understanding the defence
reaction of diseases with an elevated erythrocyte sed-
imentation rate.
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